Controlled Equity OfferingSM Sales AgreementSales Agreement • March 7th, 2019 • Cytokinetics Inc • Pharmaceutical preparations • New York
Cytokinetics, Incorporated, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
AMENDMENT NO. 8 TO COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • March 7th, 2019 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 8 to the Agreement (this “Amendment No. 8”) is entered into as of November 30, 2016 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics” or “CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
AMENDMENT NO. 9 TO COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • March 7th, 2019 • Cytokinetics Inc • Pharmaceutical preparations
This AMENDMENT NO. 9 TO COLLABORATION AND OPTION AGREEMENT (this “Amendment No. 9”) is entered into as of February 6, 2019 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics” or “CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
